



# Erratum: Follow Your Nose: A Key Clue to Understanding and Treating COVID-19

Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

## OPEN ACCESS

### Approved by:

Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

### \*Correspondence:

Frontiers Production Office  
production.office@frontiersin.org

### Specialty section:

This article was submitted to  
Cellular Endocrinology,  
a section of the journal  
Frontiers in Endocrinology

**Received:** 06 December 2021

**Accepted:** 06 December 2021

**Published:** 16 December 2021

### Citation:

Frontiers Production Office (2021)  
Erratum: Follow Your Nose:  
A Key Clue to Understanding  
and Treating COVID-19.  
*Front. Endocrinol.* 12:830164.  
doi: 10.3389/fendo.2021.830164

**Keywords:** COVID-19, mineralocorticoid receptor, spironolactone and dexamethasone, ATP - adenosine triphosphate, anosmia and ageusia

## An Erratum on

### Follow Your Nose: A Key Clue to Understanding and Treating COVID-19

by Edwards, C., Klekot, O., Halugan, L. and Korchev, Y. (2021). *Front. Endocrinol.* 12:747744. doi: 10.3389/fendo.2021.747744

Owing to a production error, several dependent variables were omitted from the part of **Table 2** that pertains to Study 1 in the article as originally published. The variables in question are mean diastolic blood pressure, breath rate, C-reactive protein concentration, D-dimer concentration, fasting glucose concentration and plasma potassium concentration. The complete part of **Table 2** that pertains to Study 1 is presented here.

The publisher apologizes for this error. The original article has been updated.

Copyright © 2021 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

**TABLE 2** | Study 1. Repeated measures analysis comparing changes in variables from baseline to 5 days treatment (T1).

Dependent variable	Treatment group	Mean baseline	Mean T1	p-value of comparison baseline vs T1	p-value of T1 comparison of Group II vs Group I
Loss of smell/taste, n	I	33 (82.5)	30 (75)	NS	<0.05
	II	34 (85)	19 (47.5)	<0.05	
Dyspnea, n	I	30 (75)	10 (25)	<0.001	NS
	II	28 (70)	8 (20)	<0.001	
Dry cough, n	I	36 (90)	18 (45)	<0.001	NS
	II	32 (80)	12 (30)	<0.001	
Fever, n	I	38 (95)	10 (25)	<0.001	NS
	II	37 (92.5)	4 (10)	<0.001	
Need for oxygen, n	I	22 (55)	7 (17.5)	NS	NS
	II	18 (45)	5 (12.5)	NS	
BP syst., mm Hg	I	130.6 ± 10.5	165.1 ± 12.1	<0.05	<0.05
	II	137.5 ± 22.5	128.3 ± 12.0	NS	
BP diast., mm Hg	I	86.0 ± 8.6	89.0 ± 10.6	NS	NS
	II	85.25 ± 12.4	81.1 ± 6.7	NS	
Breath rate/min	I	24.8 ± 4.6	18.4 ± 3.1	NS	NS
	II	24.2 ± 3.1	16.2 ± 1.8	<0.05	
CRP, mg/l	I	72.4 ± 16.7	28.1 ± 12.9	<0.05	NS
	II	65.8 ± 17.9	17.1 ± 8.7	<0.05	
D-dimer, ng/ml	I	736.7 ± 112.6	574.8 ± 106.4	NS	<0.05
	II	755.5 ± 106.1	357.3 ± 71.1	<0.001	
Fasting glucose, mmol/l	I	5.9 ± 1.5	12.69 ± 1.31	<0.05	<0.05
	II	6.9 ± 2.2	8.44 ± 1.60	NS	
[K+] plasma, mmol/l	I	4.36 ± 0.32	4.28 ± 0.50	NS	NS
	II	4.22 ± 0.40	4.43 ± 0.45	NS	

SD, standard deviation; mean BP, mean blood pressure; [K+] plasma, plasma concentration of potassium; CRP, C-reactive protein. Figures are expressed as Mean and Standard Deviation. NS, non-significant difference. No patient required ventilation: patients with oxygen saturation less than 92% given oxygen by mask.